Advertisement
Screener

United Therapeutics Corporation (UTHR) Payments to Acquire Investments

2.6 / 5 stars · 62/120 Roast Me

United Therapeutics Corporation Payments to Acquire Investments

United Therapeutics Corporation (UTHR) reported Payments to Acquire Investments of $145.70 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-04-26.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireInvestments · last filed 2017-04-26

  • United Therapeutics Corporation payments to acquire investments for the quarter ending 2017-03-31 was $145.70M.
  • United Therapeutics Corporation payments to acquire investments for the quarter ending 2016-12-31 was $28.40M.
  • United Therapeutics Corporation payments to acquire investments for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
  • United Therapeutics Corporation payments to acquire investments for the quarter ending 2015-12-31 was $0.00.
  • United Therapeutics Corporation payments to acquire investments for fiscal 2016 was $36.00M, a 33.58% decline from fiscal 2015.
  • United Therapeutics Corporation payments to acquire investments for fiscal 2015 was $54.20M, a 20.44% increase from fiscal 2014.
  • United Therapeutics Corporation payments to acquire investments for fiscal 2014 was $45.00M, a 46.27% increase from fiscal 2013.
  • United Therapeutics Corporation payments to acquire investments for fiscal 2013 was $30.77M.
Period endPayments to Acquire Investments 3 monthPayments to Acquire Investments 6 monthPayments to Acquire Investments 6 month as first filedPayments to Acquire Investments 9 monthPayments to Acquire Investments 9 month as first filedPayments to Acquire Investments 12 monthPayments to Acquire Investments 12 month as first filed
2017-03-31$145.70M
10-Q · filed 2017-04-26
$174.10M
derived: sum of 2 quarters · filed 2017-04-26
$174.10M
derived: sum of 3 quarters · filed 2017-04-26
2016-12-31$28.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22
$28.40M
derived: sum of 2 quarters · filed 2017-02-22
$36.00M
10-K · filed 2017-02-22
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27
$7.60M
10-Q · filed 2016-10-27
2016-06-30$7.60M
10-Q · filed 2016-07-28
2015-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22
$50.00M
derived: sum of 2 quarters · filed 2017-02-22
$54.20M
10-K · filed 2017-02-22
$54.22M
10-K · filed 2016-02-25
2015-09-30$50.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27
$54.20M
10-Q · filed 2016-10-27
$54.22M
10-Q · filed 2015-10-27
2015-06-30$4.20M
10-Q · filed 2016-07-28
$4.22M
10-Q · filed 2015-07-28
2014-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22
$0.00
derived: sum of 2 quarters · filed 2017-02-22
$45.00M
10-K · filed 2017-02-22
2014-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27
$45.00M
10-Q · filed 2015-10-27
2014-06-30$45.00M
10-Q · filed 2015-07-28
2013-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$0.00
derived: sum of 2 quarters · filed 2016-02-25
$30.77M
10-K · filed 2016-02-25
2013-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28
$30.77M
10-Q · filed 2014-10-28
2013-06-30$30.77M
10-Q · filed 2014-07-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17